接受免疫检查点抑制剂的患者的瘤初级护理
Christopher J Hoimes1, Suzanne McGettigan2, Lee Schwartzberg3
1Department of Medicine, Medical Oncology, Duke Cancer Institute and Center for Cancer Immunotherapy Duke University, Durham, NC; Duke Cancer Institute and Center for Cancer Immunotherapy Duke University, Durham, NC.
在接受免疫治疗的癌症患者中,初级临床医生对于管理免疫相关不良事件 (irAEs) 是至关重要的. 他们的持续护理确保及时识别和干预这些潜在的严重副作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床实践 临床实践
背景情况:
- 主要临床医生是癌症患者护理的组成部分,提供持续的支持和协调.
- 免疫检查点抑制剂 (ICI) 提供生存益处,但携带免疫相关不良事件 (irAEs) 的风险.
- 有效管理irAEs需要初级临床医生和瘤团队之间的合作.
研究的目的:
- 突出初级临床医生在管理irAEs中的关键作用.
- 强调早期识别,监测和干预IRAEs的重要性.
- 强调长期临床警在免疫瘤病人的旅程的必要性.
主要方法:
- 审查初级保健在癌症存活率中的作用.
- 分析irAE的展示和管理策略.
- 强调初级临床医生提供的护理连续性.
主要成果:
- 由于他们与患者的长期关系,初级临床医生是识别和管理IRE的关键.
- IRE可以表现为各种症状,需要谨慎监测.
- 用皮质类固醇或剂量中断的及时干预对于irAE管理至关重要.
结论:
- 主要临床医生对于确保IRAE的适当识别,监测和干预至关重要.
- 主要临床医生的持续临床警至关重要,特别是在延迟的IRE.
- 对接受免疫瘤治疗的患者来说,长期的护理连续性至关重要.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Chronic Pancreatitis II: Collaborative Care
Assessment:
